Are foot and ankle corticosteroid injections safe during the COVID-19 pandemic? A single center prospective observational study

Q2 Health Professions Foot Pub Date : 2023-09-01 DOI:10.1016/j.foot.2023.102001

Dimos Evangelidis , Su Jeong , George Lin , Naomi Ehigie , Paul Hamilton , Andrea Sott , Sohail Yousaf

{"title":"Are foot and ankle corticosteroid injections safe during the COVID-19 pandemic? A single center prospective observational study","authors":"Dimos Evangelidis , Su Jeong , George Lin , Naomi Ehigie , Paul Hamilton , Andrea Sott , Sohail Yousaf","doi":"10.1016/j.foot.2023.102001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Intra-articular corticosteroid injections (ICSI) are commonly used in orthopedic practice. Due to concerns about their immunosuppressive effects, we conducted a prospective observational audit, to monitor for COVID-19 infection amongst a group of foot and ankle patients who received an ICSI during the pandemic.</p></div><div><h3>Patients and methods</h3><p>Included were 68 patients (25 males - 43 females, mean age 59.1 years, SD 15.0, range 19 – 90 years) who received a fluoroscopy-guided ICSI within a two-month period during the pandemic. The American Society of Anaesthesiologists (ASA) grade was I in 35 % of patients, II in 58 % and III in 7 %. 16 % of patients had black, Asian or minority ethnic (BAME) background. The dose of methylprednisolone injected was 20 mg for 28 % of the patients, 40 mg for 29 % and 80 mg for 43 %.</p></div><div><h3>Results</h3><p>All patients were available for follow up at one and four weeks post-injection. None reported COVID-19 infection symptoms within this period. The only complication was a flare-up of joint pain.</p></div><div><h3>Conclusion</h3><p>Our study showed that the risk of COVID-19 infection to patients receiving foot or ankle ICSI is low. The limitations of this work must be considered, but our findings support the judicious use of corticosteroid injections during the current crisis</p></div>","PeriodicalId":12349,"journal":{"name":"Foot","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014129/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Foot","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0958259223000421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Intra-articular corticosteroid injections (ICSI) are commonly used in orthopedic practice. Due to concerns about their immunosuppressive effects, we conducted a prospective observational audit, to monitor for COVID-19 infection amongst a group of foot and ankle patients who received an ICSI during the pandemic.

Patients and methods

Included were 68 patients (25 males - 43 females, mean age 59.1 years, SD 15.0, range 19 – 90 years) who received a fluoroscopy-guided ICSI within a two-month period during the pandemic. The American Society of Anaesthesiologists (ASA) grade was I in 35 % of patients, II in 58 % and III in 7 %. 16 % of patients had black, Asian or minority ethnic (BAME) background. The dose of methylprednisolone injected was 20 mg for 28 % of the patients, 40 mg for 29 % and 80 mg for 43 %.

Results

All patients were available for follow up at one and four weeks post-injection. None reported COVID-19 infection symptoms within this period. The only complication was a flare-up of joint pain.

Conclusion

Our study showed that the risk of COVID-19 infection to patients receiving foot or ankle ICSI is low. The limitations of this work must be considered, but our findings support the judicious use of corticosteroid injections during the current crisis

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新冠肺炎大流行期间，脚和脚踝皮质类固醇注射安全吗？一项单中心前瞻性观察性研究。

背景：关节内皮质类固醇注射（ICSI）通常用于骨科实践。由于担心其免疫抑制作用，我们进行了一项前瞻性观察性审计，以监测在大流行期间接受ICSI的一组脚和踝关节患者中的新冠肺炎感染。患者和方法：包括68名患者（25名男性-43名女性，平均年龄59.1岁，SD 15.0，范围19-90岁），他们在疫情期间的两个月内接受了荧光镜引导的ICSI。美国麻醉师协会（ASA）的分级为I级35%，II级58%，III级7%。16%的患者有黑人、亚裔或少数民族（BAME）背景。28%的患者注射甲基强的松龙20 mg，29%注射40 mg，43%注射80 mg。结果：所有患者均可在注射后1周和4周进行随访。在此期间，没有人报告新冠肺炎感染症状。唯一的并发症是关节疼痛发作。结论：我们的研究表明，接受足踝ICSI的患者感染新冠肺炎的风险较低。必须考虑这项工作的局限性，但我们的研究结果支持在当前危机期间明智地使用皮质类固醇注射。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Foot Health Professions-Podiatry

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： The Foot is an international peer-reviewed journal covering all aspects of scientific approaches and medical and surgical treatment of the foot. The Foot aims to provide a multidisciplinary platform for all specialties involved in treating disorders of the foot. At present it is the only journal which provides this inter-disciplinary opportunity. Primary research papers cover a wide range of disorders of the foot and their treatment, including diabetes, vascular disease, neurological, dermatological and infectious conditions, sports injuries, biomechanics, bioengineering, orthoses and prostheses.